Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Key Stats

• Today's Range: $1.88 to $1.98
• 50-Day Range: $1.42 to $2.52
• 52-Week Range: $1.23 to $4.92
• Volume: 170,590 shs
• Average Volume: 677,837 shs
• Market Capitalization: $71.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 50% of companies evaluated by MarketBeat, and ranked 542nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Metagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Metagenomi has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Metagenomi is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Metagenomi is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Metagenomi has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.38% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently increased by 4.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.38% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently increased by 4.51%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.48

News Sentiment

Metagenomi has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Metagenomi this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for MGX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,800.00 in company stock.

Percentage Held by Insiders

17.80% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

MGX Stock Analysis - Frequently Asked Questions

How have MGX shares performed this year?

Metagenomi's stock was trading at $3.61 on January 1st, 2025. Since then, MGX shares have decreased by 46.5% and is now trading at $1.93.

How were Metagenomi's earnings last quarter?

Metagenomi, Inc. (NASDAQ:MGX) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.14. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $7.72 million. Metagenomi had a negative trailing twelve-month return on equity of 37.84% and a negative net margin of 257.99%.

When did Metagenomi IPO?

Metagenomi (MGX) raised $94 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 6,250,000 shares at $15.00 per share.

Who are Metagenomi's major shareholders?

Top institutional shareholders of Metagenomi include Pura Vida Investments LLC (2.55%), Peapod Lane Capital LLC (1.36%), Geode Capital Management LLC (0.79%) and Norges Bank (0.67%). Insiders that own company stock include Brian C Thomas, Holdings A/S Novo, Sarah B Noonberg and Pamela Wapnick.
View institutional ownership trends.

How do I buy shares of Metagenomi?

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Metagenomi own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/25/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 236
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Metagenomi: $10.00
• High Price Target: $12.00
• Low Price Target: $7.00
• Potential Upside/Downside: +417.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.06 million
• Net Margins: -257.99%
• Pretax Margin: -267.38%
• Return on Equity: -37.84%
• Return on Assets: -27.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.36
• Quick Ratio: 6.36

Sales & Book Value

• Annual Sales: $52.29 million
• Price / Sales: 1.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.28 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 37,530,000
• Free Float: 30,852,000
• Market Cap: $72.58 million
• Optionable: N/A
• Beta: -0.12